Australia markets open in 4 hours 41 minutes

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
29.76+0.90 (+3.12%)
As of 03:18PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close28.86
Open28.82
Bid29.67 x 100
Ask29.86 x 100
Day's range28.48 - 30.30
52-week range17.53 - 45.58
Volume475,762
Avg. volume1,160,573
Market cap4.324B
Beta (5Y monthly)0.70
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    5 Biotech Stocks Worth Adding to Your Portfolio in 2024

    New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.

  • Insider Monkey

    Should You Hold Immunovant (IMVT)?

    Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]

  • Zacks

    Here's Why You Should Add Immunovant (IMVT) to Your Portfolio

    Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.